COMP <GO>
ABT vs MRK // OPERATING MARGIN
Abbott Laboratories (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ABT 6
— MRK 9
▲ OPERATING MARGIN LEADER: MRK
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
operating-margins
18.20%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
operating-margins
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 74.80% | -18.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 20.70% | -8.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 15.3x | +3.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 3.42% | +0.67 | ABT | /fcf-yield <GO> |
| Operating Margin ACTIVE | 18.20% | 34.30% | -16.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 28.10% | -13.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 1.30% | +4.40 | ABT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.26% | +0.01 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 5.19 | -0.83 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.5 | 56.9 | +2.66 | ABT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | ABT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 18.4x | +7.40 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $180.95B | $361.02B | -$180.08B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | MRK REV | ABT GROSS % | MRK GROSS % | ABT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $65.01B | 56.4% | 74.8% | $7.39B | $12.36B |
| FY 2024 | $41.95B | $64.17B | 55.4% | 76.3% | $6.35B | $18.10B |
| FY 2023 | $40.11B | $60.12B | 44.0% | 44.0% | $5.46B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
MRK // BETA 0.92